--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

Biocon is introducing Bosaya (denosumab-kyqq), a biosimilar to Prolia, and Aukelso (denosumab-kyqq), a biosimilar to Xgeva.

Mabwell (688062.SH), an innovative biopharmaceutical company with a full industry chain, announced that the National Medical ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

Biocon announced the launch of Bosaya™ and Aukelso™ (denosumab-kyqq) in the U.S. and available by prescription nationwide.

Question: I changed my insurance for 2026 and I am having trouble with my Prolia shot – what are my options? Answer: First let me explain what Prolia is for those that may not know. Prolia is a ...

(RTTNews) - Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Bosaya ...

Apotex Inc. ("Apotex" or the "Company"), the largest Canadian‑based global pharmaceutical company, today announced that Health Canada has approved DENOZA™ (denosumab injection), a biosimilar ...

Biocon launches two FDA-approved interchangeable denosumab biosimilars in the US, targeting osteoporosis and bone metastasis in a $5B market.